The Rise and Fall (and Rise Again?) of Hims & Hers: A Telehealth Titan and Its Turbocharged ETF Twin

In the ever-evolving world of healthcare, few companies have captured the zeitgeist quite like Hims & Hers Health Inc. ($HIMS). What started as a discreet online service for men's wellness—think hair loss treatments and ED meds—has ballooned into a full-fledged telehealth empire, tackling everything from mental health to weight loss. But in the stock market's wild ride, $HIMS isn't just a stock anymore; it's the star of its own leveraged ETF show with $HIMZ, the Defiance Daily Target 2X Long HIMS ETF. Buckle up as we dive into this duo's story: innovation, volatility, and why they're a magnet for thrill-seeking investors.

The Origin Story: From Taboo Topics to Mainstream Medicine

Hims & Hers launched in 2017 with a mission to make healthcare accessible and stigma-free. No more awkward doctor visits for sensitive issues—just a few clicks, a virtual consultation, and discreet deliveries to your door. Fast-forward to today, and the company (NYSE: HIMS) has expanded into women's health (hence the "Hers" part), skincare, vitamins, and even compounded GLP-1 drugs for weight management—riding the Ozempic wave without the Big Pharma price tag.

What makes $HIMS fascinating isn't just its product lineup; it's the business model. By leveraging telehealth, they've cut out middlemen, reduced costs, and scaled rapidly. Revenue has skyrocketed from $82 million in 2019 to over $1 billion projected for 2025, with subscriber growth hitting millions. But it's not all smooth sailing—the stock has been a rollercoaster, peaking at $25 in 2021 amid SPAC hype, crashing to $5 during the 2022 bear market, and surging back to $30+ in 2025 on weight-loss drug buzz.

Imagine logging into an app, chatting with a doctor about your anxiety or skin woes, and getting personalized treatments shipped overnight. That's the magic of telehealth, and Hims & Hers is at the forefront, blending tech with wellness in a way that's both innovative and profitable. Yet, controversies lurk: critics question the ethics of direct-to-consumer meds, and regulatory scrutiny on compounded drugs adds spice to the narrative.

Enter $HIMZ: Double the Thrills, Double the Chills

If $HIMS is the steady (ish) horse, $HIMZ is the rocket-fueled stallion. Launched in March 2025 by Defiance ETFs, this leveraged fund aims to deliver twice the daily performance of HIMS stock—before fees and expenses. It's not for the faint-hearted; leveraged ETFs like this use derivatives (swaps and options) to amplify gains... and losses.

Why create an ETF just for one stock? Hims & Hers has become a cult favorite among retail investors, thanks to its meme-stock vibes and ties to hot trends like anti-aging and obesity treatments. $HIMZ lets traders bet big on short-term swings without options' complexity. But here's the plot twist: in June 2025, $HIMZ cratered 70% in a single day when Novo Nordisk ended a key partnership with Hims & Hers, wiping out billions in market value. Ouch—that's the dark side of leverage, where a 35% drop in $HIMS becomes a 70% nightmare for $HIMZ holders.

As of January 2026, $HIMZ trades around $5-6, with assets under management hovering at $120 million. It's a high-octane play for day traders chasing volatility, but experts warn: hold it long-term, and compounding effects plus a 1.29% expense ratio could erode returns. Think of it as caffeine for your portfolio—great in bursts, disastrous if overdone.

The Bigger Picture: Health, Hype, and Hazards

$HIMS and $HIMZ embody the intersection of healthcare innovation and market mania. On one hand, Hims & Hers is democratizing access to care, potentially disrupting giants like CVS or UnitedHealth. Their foray into personalized medicine and AI-driven consultations could make them a $100+ stock in the coming years—if they navigate FDA hurdles and competition.

On the flip side, the duo highlights stock market risks. $HIMS insiders selling shares? Par for the course in growth stocks. But for $HIMZ, it's amplified: a bad earnings report or partnership flop, and you're looking at wipeout territory. Recent X chatter shows bulls pounding the table for a rebound to $120, while bears eye $25 support levels. Trump's "Great Health Care Plan" could shake things up too, potentially boosting direct-to-consumer models like Hims.

Final Thoughts: Bet on Health or Gamble on Gains?

Whether you're a wellness warrior stocking up on Hims gummies or a trader eyeing $HIMZ for that quick flip, this pair is a microcosm of modern investing: tech-driven disruption meets speculative frenzy. If Hims & Hers keeps innovating, $HIMS could be a portfolio staple. As for $HIMZ? It's the adrenaline junkie's tool—fun until it's not.

In a world where health is wealth, these two remind us: sometimes, the biggest gains come with the biggest risks. What's your take—bullish on the bounce or bracing for more drama? Drop a comment below!